Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1165-1173

  Isaka, Masanori ^a   Yasuda, Yoko ^a   Taniguchi, Tooru ^a   Kozuka, Satoshi ^b   Matano, Keiko ^a   Maeyama, Jun Ichi ^c   Morokuma, Kazunori ^d   Ohkuma, Kunio ^d   Goto, Norihisa ^c   Tochikubo, Kunio ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Chukyo Women's University   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Acellular pertussis vaccine; Intranasal immunization; Mucosal vaccination; Recombinant cholera toxin B subunit (rCTB)

Indexed keywords

ADJUVANT; ALUMINUM; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA TOXOID; HEPATITIS B VACCINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS VACCINE; TETANUS TOXOID; TOXOID;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE CALCULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROVOCATION TEST;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHOLERA TOXIN; FEMALE; FORMALDEHYDE; HEMAGGLUTININS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; PERTUSSIS VACCINE; RECOMBINANT PROTEINS; TOXOIDS; VACCINATION; VACCINES, ACELLULAR; VACCINES, COMBINED; VAGINA; VIRULENCE FACTORS, BORDETELLA;

EID: 0037424182     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00516-9     Document Type: Article

References (46)

1. Weiss A. Mucosal immune defenses and the response of Bordetella pertussis. ASM News. 63(1):1997;22-28.
2. Fine P.E.M., Clarkson J.A. Distribution of immunity to pertussis in the population of England and Wales. J. Hyg. Camb. 92:1984;21-36.
3. Barraff L.J., Cody C.L., Cherry J.D. DTP associated reactions: an analysis by injection site, manufacturer, prior reactions and dose. Pediatrics. 73:1984;31-36.
4. Pollock T.M., Mortimer J.Y., Miller E., Smith G. Symptoms after primary immunization with DTP and DT vaccine. Lancet. 2:1984;146-149.
5. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. i:1984;122-126.
6. Sato Y., Sato H. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals. Dev. Biol. Stand. 73:1991;251-262.
7. Elson CO. Cholera toxin as a mucosal adjuvant. In: Kiyono H, Orga PL, McGhee JR, editors. Mucosal vaccines. San Diego (CA): Academic Press; 1996. p. 59-72.
8. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6:1988;269-277.
9. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP ribosyl-transferase activity. Eur. J. Immunol. 22:1992;2277-2281.
10. Ruedl C., Rieser C., Kofler N., Wick G., Wolf H. Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin. Vaccine. 14(8):1996;792-798.
11. Takahashi I., Marinaro M., Kiyono H.et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173(3):1996;627-635.
12. DeHaan L., Holtrop M., Verweij W.R., Agsteribbe E., Wilscht J. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. Vaccine. 14(4):1996;260-266.
13. Katz J.M., Lu X., Young S.A., Galphin J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175(2):1997;352-363.
14. Douce G., Turcotte C., Cropley I.et al. Mutants of Escherichia coli-heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic mucosal adjuvants. Proc. Nalt. Acad. Sci. U.S.A. 92:1995;1644-1648.
15. Di Tommaso A., Saletti G., Pizza M.et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64(3):1996;974-979.
16. Yamamoto S., Kiyono H., Yamamoto M.et al. A nontoxic mutant of cholera toxin elicits Th-2 type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5267-5272.
17. Douce G., Fontana M., Pizza M.et al. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65(7):1997;2821-2828.
18. O'Neal C.M., Clements J.D., Estes M.K., Conner M.E. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72(4):1998;3390-3393.
19. DeHaan L., Feil I.K., Verweij W.R.et al. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. 28:1998;1243-1250.
20. Barackman J.D., Ott G., O'Hagan D.T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect. Immun. 67(8):1999;4276-4279.
21. Hagiwara Y., Komase K., Che Z.et al. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine. 17(22):1999;2918-2926.
22. Del Giudice G., Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine. 17(Suppl. 2):1999;S44-S52.
23. Tochikubo K., Isaka M., Yasuda Y.et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine. 16(2-3):1998;150-155.
24. Isaka M., Yasuda Y., Kozuka S.et al. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine. 16(17):1998;1620-1626.
25. Isaka M., Yasuda Y., Kozuka S.et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 18(7-8):2000;743-751.
26. Kozuka S., Yasuda Y., Isaka M.et al. Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity. Vaccine. 18(17):2000;1730-1737.
27. Isaka M., Yasuda Y., Mizokami M.et al. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine. 19(11-12):2001;1460-1466.
28. Wu H.-Y., Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine. 16(2-3):1998;286-292.
29. Verweij W.R., DeHaan L., Holtrop M.et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine. 16(20):1998;2069-2076.
30. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol. Lett. 111(2-3):1993;219-224.
31. Yasuda Y., Matano K., Asai T., Tochikubo K. Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant. FEMS Immunol. Med. Microbiol. 20(4):1998;311-318.
32. Goto N., Maeyama J., Yasuda Y.et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine. 18(20):2000;2164-2171.
33. Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect. Immun. 46(2):1984;415-421.
34. Sakaguchi M., Inouye S., Miyazawa H., Tamura S. Measurement of antigen-specific mouse IgE by a fluorometric reverse (IgE-capture) ELISA. J. Immunol. Meth. 116:1989;181-187.
35. Guiso N., Capiau C., Carletti G., Poolman J., Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine. 17(19):1999;2366-2376.
36. Roberts M., Bacon A., Rappuoli R.et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63(6):1995;2100-2108.
37. Jabbal-Gill I., Fisher A.N., Rappuoli R.et al. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine. 16(20):1998;2039-2046.
38. Ryan E.J., McNeela E., Murphy G.A.et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67(12):1999;6270-6280.
39. Ishii R., Nakajima N., Goshima T.et al. Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice. Kansenshogaku Zasshi. 73(11):1999;1145-1152. (in Japanese).
40. Cahill E.S., O'Hagan D.T., Illum L.et al. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine. 13(5):1995;455-462.
41. Shahin R.D., Amsbaugh D.F., Leef M.F. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun. 60(4):1992;1482-1488.
42. Cahill E.S., O'Hagan D.T., Illum L., Redhead K. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. FEMS Microbiol. Lett. 107:1993;211-216.
43. Roberts M., Cropley I., Chatfield S., Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine. 11:1993;866-872.
44. Munoz JJ. Action of pertussigen (pertussis toxin) on the host immune system. In: Wardlaw AC, Parton R, editors. Pathogenesis and immunity in pertussis. NY: Wiley; 1988. p. 173-92.
45. Ui M. The multiple biological activities of pertussis toxin. In: Wardlaw AC, Parton R, editors. Pathogenesis and immunity in pertussis. NY: Wiley; 1988. p. 121-45.
46. Berstad A.K.H., Oftung F., Korsvold G.E.et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine. 18(22):2000;2323-2330.